Hot Sale CAS 366789-02-8 Rivaroxaban

Details:

Company Information:

Hebei Mojin Biotechnology Co., Ltd, Our company is a professional in lead acetate, diphenyl ethylamine and other chemical raw materials and chemical reagents research and development production enterprises. Our business covers more than 30 countries, most of the big customers come from Europe, America and other countries in the world, we can guarantee the quality and price. In recent decades, with the efforts of all employees, we have established many cooperative companies in shandong, henan, guangdong and other places. Our corporate purpose is based on the market, enhance the strength, take the road of scientific and environmental sustainable development, relying on the country. Technology r & d center, increase the investment in r & d, based on the domestic market, expand the international market, manufacturing quality products, sincere service to the society, into a modern, ecological, scientific and technological enterprise world.

What is Rivaroxaban 

Rivaroxaban has a similar chemical structure to that of the Astragaloside IV molecule, but it is smaller and significantly more bioavailable, enabling lower doses to be taken. It is already used as an immunostimulant because of its ability to increase T lymphocyte proliferation. However, it is its exceptional anti-aging properties that are of increasing interest to the scientific community.Rivaroxaban stimulates the repair of DNA damage by activating telomerase, a nucleoprotein enzyme which catalyses synthesis and growth of telomeric DNA. Telomeres are made of thin filaments and are found at the tips of chromosomes. Maintaining their stability enables cells to avoid replicative senescence and indefinite proliferation beyond the 'Hayflick limit'. Telomeres shorten with each cycle of cell division, or when subjected to oxidative stress. Until now, this has been an unavoidable mechanism of aging.

Fuction and Application of Rivaroxaban

1. For adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE).
2. For the treatment of adult venous thrombosis (DVT), reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT.
3. For adult patients with non-valvular atrial fibrillation with one or more risk factors (eg, congestive heart failure, hypertension, age ≥75 years, diabetes, stroke, or transient ischemic attack), Reduce the risk of stroke and systemic embolism.